The Food and Drug Administration (FDA) did not approve glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) (semaglutide) tablets for drug‐naive type 2 diabetes until January 2023.2 The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.